56. (Amended) A method of combating a viral infection in a subject in need of such treatment comprising administering to said subject an effective infection-combating amount of a compound of Formula III



(III)

wherein: R_1 is a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3;

R_2 is a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3; and

Z is a moiety of the Formula V,



(V)

wherein: V is H or N_3;

W is H or F; or

V and W together are a covalent bond; and

B is a purinyl moiety of Formula VI



(VI)

optionally substituted at position 2 with [=O] -OH, -SH, $-NH_2$, or halogen, [at position 4 with NH_2 or =O,] at position 6 with Cl, $-NH_2$, -OH, or C_1-C_3 alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



(VII)

substituted at position 4 with =O or NH_2 and optionally substituted at position 5 with halogen or C_1-C_3 saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen;
or a pharmaceutical salt thereof.

58. (Amended) A method according to claim 56, wherein R_1 is unbranched C_8 alkyl.

59. (Amended) A method according to claim 56, wherein R_1 is unbranched C_{10} alkyl.

60. (Amended) A method according to claim 56, wherein R_1 is unbranched C_{12} alkyl.

62. (Amended) A method according to claim 56, wherein R_2 is unbranched C_8 alkyl.

63. (Amended) A method according to claim 56, wherein R_2 is unbranched C_{10} alkyl.

64. (Amended) A method according to claim 56, wherein R_2 is unbranched C_{12} alkyl.

65. (Amended) A method according to claim 56, wherein X is [NCO] NHCO.

95. (Amended) A compound of Formula III

C5

E3 cont



(III)

wherein: R_1 is a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3;

R_2 is a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3; and

Z is a moiety of the Formula V,



(V)

wherein: V is H or N_3;

W is H or F; or

V and W together are a covalent bond; and

C5

E3

E cont

B is a purinyl moiety of Formula VI



(VI)

optionally substituted at position 2 with [=O] -OH, -SH, $-NH_2$, or halogen, [at position 4 with NH_2 or =O,] at position 6 with Cl, $-NH_2$, -OH, or C_1-C_3 alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



(VII)

substituted at position 4 with =O or NH_2 and optionally substituted at position 5 with halogen or C_1-C_3 saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen.

C6

101. (Amended) A method of combating tumors in a subject in need of such treatment comprising administering to said subject an effective amount of a compound of Formula III

E

C6



(III)

wherein: R_1 is a branched or unbranched, saturated or unsaturated C_6 to C_{18} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

X is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3;

R_2 is a branched or unbranched, saturated or unsaturated C_6 to C_{14} alkyl group optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amine, or substituted or unsubstituted aromatic;

Y is selected from the group consisting of NHCO, CH_3NCO, CONH, $CONCH_3$, S, SO, SO_2, O, NH, and NCH_3; and

Z is a moiety of the Formula V,



(V)

wherein: V is H or N_3;

W is H or F; or

V and W together are a covalent bond; and

C6

B is a purinyl moiety of Formula VI



(VI)

optionally substituted at position 2 with [=O] -OH, -SH, $-NH_2$, or halogen, [at position 4 with NH_2 or =O,] at position 6 with Cl, $-NH_2$, -OH, or C_1-C_3 alkyl, and at position 8 with Br or I; or

B is a pyrimidinyl moiety of Formula VII



(VII)

substituted at position 4 with =O or NH_2 and optionally substituted at position 5 with halogen or C_1-C_3 saturated or unsaturated alkyl optionally substituted 1 to 3 times with halogen;

or a pharmaceutical salt thereof.